Last Updated: Friday, 19 October 2007, 17:23 GMT 18:23 UK

E-mail this to a friend
Printable version


Muscular dystrophy trial to start
By Fergus Walsh
Medical correspondent, BBC News


Daniel is taking part in the trial
A gene therapy trial for the fatal disorder Duchenne muscular dystrophy (DMD) is about to begin in London.
In a world first, a small group of patients will be injected with an experimental drug which it is hoped will extend their lives.
DMD, which affects boys, is caused by a single faulty gene, and results in progressive muscle wasting.
The injection contains a "molecular patch" targeting the faulty gene so that it should work again.
HOW THERAPY WORKS
A single faulty gene on the x-chromosome causes Duchenne Muscular Dystrophy
There are some small errors in the genetic code on the gene which means that it is unable to produce the dystrophin protein which keeps muscles strong.
The treatment involves scientists making a very small piece of genetic material - a molecular patch which once inside the muscle cell, binds to the piece of code which surrounds the genetic error
This enables the gene to produce a working version of the dystrophin gene. It's been tested successfully in mice but these will be the first tests in humans
At first, minute quantities of the drug will be used - to check it is safe.
If it works the drug will effectively knit together the key damaged section of DNA, allowing it to begin producing a protein that keeps the muscles strong.
The hope is it could slow, or even halt the progression of muscle wasting, and give some patients the chance of living into old age.
Animal trials of the drug have proved highly successful.
If it works in humans, patients would need regular infusions of the drug.
Lead researcher Professor Francesco Muntoni, of Imperial College London, has high hopes.
He said: "It will be truly life changing, and life extending for these people. "Maybe this will not be a complete cure, but it could definitely buy a lot of time for these children."
Professor Muntoni describes the gene therapy as like a piece of molecular velcro which will form a temporary repair.

Daniel has high hopes for the future
Gene therapy will work best in young children, as it cannot reverse existing muscle damage.
Daniel Emerson-Smith used to be able to run around and kick a football, but DMD is gradually destroying all the strength in his body.
He is just 16 and now needs a wheelchair to get around. People with DMD rarely live beyond their 20s.
But Daniel is hopeful that taking part in the trial will transform his prospects.
He said: "I think it will help me live longer, and slow down the illness a bit.
"I will be able to move around a bit more, and have some independence, and maybe take my Mum out."
This is the first time that results from this type of research are so close to being translated into a treatment

Dr Marita Pohlschmidt
Muscular Dystrophy Campaign
Nick Caitlin, of the charity Parent Project UK, which has partly funded the trial, said: "This is a real red letter day for all the parents who have campaigned tirelessly over the last couple of years to get funding for treatments or a cure for Duchenne

Views: 149

Reply to This

Replies to This Discussion

Is this for skipping exon 51?
Is this gene therapy for all DMD patients or patients with specific mutations?
hi there, I was just sent this, i foregot to write in my above email, i am trying to find out what this is, if you type in the google box bbc duchenne, it will take you to this page, and it is the news station. they Play a video too..
I think this is the exon skipping trial? skipping exon 51. Pls correct me if I am wrong
Yes, it is the exon skipping trial conducted by MDEX&AVIBio skipping 51.

Reply to Discussion

RSS

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2021   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service